Semarion to join the Start Codon programme and receive £250k pre-seed investment

22nd June 2020

Start Codon, a new model of life science and healthcare business accelerator, today proudly debuts its first cohort of startup companies. Start Codon aims to minimise risk and translate early stage research into successful startups, ready for funding and partnership. Start Codon has worked closely with four exciting life science and healthcare companies that were enrolled into the programme in February this year.

Semarion is excited to join Start Codon’s first cohort, which includes business support and £250k in pre-seed capital.

Join Start Codon:
Read the Press Release:

Overview of cohort companies:

  • Enhanc3D Genomics, a functional genomics spinout of the Babraham Institute (Cambridge, UK) whose platform technology links noncoding sequence variants to their target genes in order to identify novel therapeutic targets
  • Drishti Discoveries, a startup leveraging a proprietary gene silencing technology to develop therapies for rare inherited diseases
  • Spirea, a spinout from the University of Cambridge, who is developing the next generation of antibody drug conjugate cancer therapeutics which carry more drug payload to tumour cells, resulting in greater efficacy, tolerability and the ability to treat more cancer patients
  • Semarion, a University of Cambridge spinout, who is revolutionising cellbased assays for  drug discovery and life science through its proprietary SemaCyte® microcarrier platform, which leverages novel materials physics for assay miniaturisation, multiplexing, and automation